HBV vaccine and risk of developing multiple sclerosis: a systematic review and meta-analysis

References

• Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2009;30(12):2212–2219. doi:10.1016/j.vaccine.2011.12.116.
   Web of Science ®Google Scholar
• A S L, McMahon BJ. Chronic Hepatitis B. Hepatology. 2007;45(25):507–539. doi:10.1002/hep.21513.
   PubMed Web of Science ®Google Scholar
• Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol. 2006;78(2):169–177. doi:10.1002/jmv.20524.
   PubMed Web of Science ®Google Scholar
• Buynak EB, Roehm RR, Tytell AA, Bertland AU, Lampson GP, Hilleman MR. Development and chimpanzee testing of a vaccine against human hepatitis B. Proc Soc Exp Biol Med. 1976;151(4):694–700.
   PubMed Web of Science ®Google Scholar
• Gout O, Lyon-Caen O. Multiple sclerosis and hepatitis B vaccination Sclerose en plaques et vaccination contre le virus de l’hepatite B. Rev Neurol. 1998;154(3):205–207.
   PubMed Web of Science ®Google Scholar
• Tourbah A, Gout O, Liblau R, Lyon-Caen O, Bougniot C, Iba-Zizen MT, Cabanis EA. Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS? Neurology. 1999;53(2):396–401. doi:10.1212/WNL.53.2.396.
   PubMed Web of Science ®Google Scholar
• Fourrier A, Touzé E, Alpérovitch A, Bégaud B. Association between hepatitis B vaccine and multiple sclerosis. Pharmacoepidemiol Drug Safety. 1999;8(Suppl):S140–S141.
   Google Scholar
• Sturkenboom M, Wolfson C, Roullet E, Heinzlef O, Abenhaim L. Demyelination, multiple sclerosis, and hepatitis B vaccination: A population-based study in the UK. Neurology. 2000;54(7):A166.
   Web of Science ®Google Scholar
• Rouge-Maillart CI, Guillaume N, Jousset N, Penneau M. Recognition by French courts of compensation for post-vaccination multiple sclerosis: the consequences with regard to expert practice. Med Sci Law. 2007;47(3):185–190. doi:10.1258/rsmmsl.47.3.185.
   PubMed Web of Science ®Google Scholar
• Demicheli V, Rivetti A, Pietrantonj CD, Clements C, Jefferson T. Hepatitis B vaccination and multiple sclerosis: evidence from a systematic review. J Viral Hepat. 2003;10(5):343–344. doi:10.1046/j.1365-2893.2003.00423.x.
   PubMed Web of Science ®Google Scholar
• Martínez-Sernández V, Figueiras A. Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production. J Neurol. 2013;260(8):1951–1959. doi:10.1007/s00415-012-6683-3.
   PubMed Web of Science ®Google Scholar
• Mouchet J, Salvo F, Raschi E, Poluzzi E, Antonazzo IC, De Ponti F, Bégaud B. Hepatitis B vaccination and the putative risk of central demyelinating diseases–A systematic review and meta-analysis. Vaccine. 2018;36(12):1548–1555. doi:10.1016/j.vaccine.2018.02.036.
   PubMed Web of Science ®Google Scholar
• Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol. 2011;258(7):1197–1206. doi:10.1007/s00415-011-5984-2.
   PubMed Web of Science ®Google Scholar
• Hocine MN, Farrington CP, Touzé E, Whitaker HJ, Fourrier A, Moreau T. Tubert-Bitter P Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case–control study using the self-controlled case series method. Vaccine. 2007;25(31):5938–5943. doi:10.1016/j.vaccine.2007.05.032.
   PubMed Web of Science ®Google Scholar
• Mikaeloff Y, Caridade G, Suissa S, Tardieu M. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology. 2009;72(10):873–880. doi:10.1212/WNL.0b013e3181a9fad1.
   PubMed Web of Science ®Google Scholar
• Touze E, Gout O, Verdier-Taillefer MH, Lyon-Caen O, Alperovitch A. First central nervous system demyelination and hepatitis B vaccination: a pilot case control study. Rev Neurol. 2000;156(3):242–246.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Brodovicz K, Walker AM. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med. 2001;344(5):327–332. doi:10.1056/NEJM200102013440502.
   PubMed Web of Science ®Google Scholar
• Eftekharian MM, Mousavi M, Hormoz MB, Roshanaei G, Mazdeh M. Multiple sclerosis and immunological-related risk factors: results from a case-control study. Human Antibodies. 2015;23(1,2):31–36.
   Google Scholar
• Hernán MA, S S J, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology. 2004;63(5):838–842.
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Qian L, Tartof SY, Brara SM, Jacobsen SJ, Beaber BE, Sy LS, Chao C, Hechter R, Tseng HF. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA neurol. 2014;71(12):1506–1513. doi:10.1001/jamaneurol.2014.2633.
   PubMed Web of Science ®Google Scholar
• Mikaeloff Y, Caridade G, Rossier M, Suissa S, Tardieu M. Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. Arch Pediatr Adolesc Med. 161(12):1176–1182. doi:10.1001/archpedi.161.12.1176.
   PubMedGoogle Scholar
• Ramagopalan SV, Valdar W, Dyment DA, DeLuca GC, Yee IM, Giovannoni G. Ebers GC Group Canadian Collaborative Study. Association of infectious mononucleosis with multiple sclerosis. A population-based study. Neuroepidemiology. 2009;32(4):257–262. doi:10.1159/000201564.
   PubMed Web of Science ®Google Scholar
• Touzé E, Fourrier A, Rue-Fenouche C, Rondé-Oustau V, Jeantaud I, Bégaud B, Alpérovitch A. Vaccination and first central nervous system demyelinating event: acase-control study. Neuroepidemiology. 2002;21(4):180–186.
   PubMed Web of Science ®Google Scholar
• Rutschmann OT, McCrory DC, Matchar DB; Guidelines IPotMSCfCP. Immunization and MS A summary of published evidence and recommendations. Neurology. 2002;59(12):1837–1843. doi:10.1212/WNL.59.12.1837.
   PubMed Web of Science ®Google Scholar
• Belbasis L, Bellou V, Evangelou E, Ioannidis JPA. Tzoulaki, I Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 2015;14(3):263–273. doi:10.1016/S1474-4422(14)70267-4.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Group P Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Andersson T, Ahlbom A. Meta-analysis. In: Rothman K, editor. EPISHEET: Spreadsheets for the analysis of epidemiological data. Boston; 2003.
   Google Scholar